Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      1 Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
      2 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA
      3 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
      4 Center for Precision Environmental Health, Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX
      5 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      6 Departments of Pediatrics and Medicine, Division of Hematology, UNC School of Medicine, Chapel Hill, NC
      7 Department of Genomic Medicine, the University of Texas M.D. Anderson Cancer Center, Houston, TX
      8 Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
      9 Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
      10 Translational Surgical Pathology Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
      11 Division of Pediatric Hematology/Oncology, BronxCare Health System, Bronx, NY
      12 Division of Pediatric Oncology, Children’s National Medical Center, Washington, DC
      13 Division of Pediatric Hematology/Oncology, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
      14 Division of Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH
      15 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
      16 Department of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, TX
      17 Center for Cancer Epigenetics, The University of Texas M.D. Anderson Cancer Center, Houston, TX
      18 Division of Nephrology, Children’s National Medical Center, Washington, DC
      19 Department of Urology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
      20 Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
      21 Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
    • Keywords:
      INI1
      Renal cell carcinoma
      Sickle hemoglobinopathies
      SMARCB1
      Unclassified renal cell carcinoma with medullary phenotype
    • Abstract:
      Renal medullary carcinoma (RMC) is one of the most aggressive renal cell carcinomas. It predominantly afflicts young adults and adolescents with sickle cell trait and other sickle hemoglobinopathies, and is refractory to targeted and antiangiogenic therapies used in patients with clear-cell renal cell carcinoma. Platinum-based cytotoxic chemotherapy is the mainstay for RMC treatment. On the basis of recent advances in the diagnosis, management, and clinical trial development for RMC, a panel of experts met in October 2017 and developed updated consensus recommendations to inform clinicians, researchers, and patients. Because RMC often aggressively recurs while patients are still recovering from nephrectomy, upfront chemotherapy should be considered for most patients, including those with localized disease. After safety and dosing information has been established in adults, phase II and III trials enrolling patients with RMC should allow patients aged 12 years and older to be accrued. Patients with the very rare unclassified renal cell carcinoma with medullary phenotype variant should be included in RMC trials. Medical providers should be aware that RMC can afflict subjects of all races, and not only those of African descent, and that the presence of sickle cell trait, or of other sickle hemoglobinopathies, can affect drug responses and toxicity.
    • ISSN:
      1558-7673
    • Accession Number:
      10.1016/j.clgc.2018.09.005
    • Accession Number:
      S1558767318303847
    • Copyright:
      © 2018 Elsevier Inc. All rights reserved.
  • Citations
    • ABNT:
      MSAOUEL, P. et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, [s. l.], v. 17, n. 1, p. 1–6, 2019. DOI 10.1016/j.clgc.2018.09.005. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S1558767318303847. Acesso em: 4 ago. 2020.
    • AMA:
      Msaouel P, Hong AL, Mullen EA, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer. 2019;17(1):1-6. doi:10.1016/j.clgc.2018.09.005.
    • AMA11:
      Msaouel P, Hong AL, Mullen EA, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer. 2019;17(1):1-6. doi:10.1016/j.clgc.2018.09.005
    • APA:
      Msaouel, P., Hong, A. L., Mullen, E. A., Atkins, M. B., Walker, C. L., Lee, C.-H., Carden, M. A., Genovese, G., Linehan, W. M., Rao, P., Merino, M. J., Grodman, H., Dome, J. S., Fernandez, C. V., Geller, J. I., Apolo, A. B., Daw, N. C., Hodges, H. C., Moxey-Mims, M., … Tannir, N. M. (2019). Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 17(1), 1–6. https://doi.org/10.1016/j.clgc.2018.09.005
    • Chicago/Turabian: Author-Date:
      Msaouel, Pavlos, Andrew L. Hong, Elizabeth A. Mullen, Michael B. Atkins, Cheryl Lyn Walker, Chung-Han Lee, Marcus A. Carden, et al. 2019. “Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.” Clinical Genitourinary Cancer 17 (1): 1–6. doi:10.1016/j.clgc.2018.09.005.
    • Harvard:
      Msaouel, P. et al. (2019) ‘Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma’, Clinical Genitourinary Cancer, 17(1), pp. 1–6. doi: 10.1016/j.clgc.2018.09.005.
    • Harvard: Australian:
      Msaouel, P, Hong, AL, Mullen, EA, Atkins, MB, Walker, CL, Lee, C-H, Carden, MA, Genovese, G, Linehan, WM, Rao, P, Merino, MJ, Grodman, H, Dome, JS, Fernandez, CV, Geller, JI, Apolo, AB, Daw, NC, Hodges, HC, Moxey-Mims, M, Wei, D, Bottaro, DP, Staehler, M, Karam, JA, Rathmell, WK & Tannir, NM 2019, ‘Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma’, Clinical Genitourinary Cancer, vol. 17, no. 1, pp. 1–6, viewed 4 August 2020, .
    • MLA:
      Msaouel, Pavlos, et al. “Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.” Clinical Genitourinary Cancer, vol. 17, no. 1, Feb. 2019, pp. 1–6. EBSCOhost, doi:10.1016/j.clgc.2018.09.005.
    • Chicago/Turabian: Humanities:
      Msaouel, Pavlos, Andrew L. Hong, Elizabeth A. Mullen, Michael B. Atkins, Cheryl Lyn Walker, Chung-Han Lee, Marcus A. Carden, et al. “Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.” Clinical Genitourinary Cancer 17, no. 1 (February 1, 2019): 1–6. doi:10.1016/j.clgc.2018.09.005.
    • Vancouver/ICMJE:
      Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee C-H, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer [Internet]. 2019 Feb 1 [cited 2020 Aug 4];17(1):1–6. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S1558767318303847